Studies show RV reduces hyperphosphorylated tau levels in AD mice by decreasing CDK5 and GSK3β activity, preventing tau phosphorylation at Ser396, and lowering p-tau levels in the cortex (p < 0.01) and hippocampus (p < 0.05). Here, CDK5 is linked to Alzheimer disease.